UK: But Finishing Was Never Part Of The (Paediatric Investigation) Plan…

Last Updated: 26 February 2014
Article by Stephen Duffield

The UK's High Court recently decided upon Dr Reddy's application to revoke the 6 month paediatric extension of Warner-Lambert's SPC for atorvastatin (Lipitor), which is used for lowering blood cholesterol.

Background

SPCs are granted to compensate patent holders for the time taken to obtain marketing authorisation for a medicine covered by a patent. An SPC comes into effect at the end of the patent's term. It extends the protection for the authorised medicine for a period equal to that between the filing date of the patent and the date of the first marketing authorisation, to a maximum of 5 years.

Provision for the extension of SPCs was introduced by Regulation 1901/2006 ("the paediatric regulation") which took effect in January 2007. The regulation's purpose is to encourage research into the use of medicines in children. This research is considered to be important, because, as noted in Recital 3 of the regulation, a lack of information in this area leads to increased risks of adverse reactions, ineffective treatment through under-dosage, and the non-availability to the paediatric population of therapeutic advances, suitable formulations and routes of administration. In this regard, however, there is no requirement that a medicine be authorised for paediatric use for an extension to the SPC to be granted following the research.

The discovery that the medicine is not effective in the paediatric population is also considered valuable information.

Briefly, in order to obtain a paediatric extension, the applicant must complete a number of steps, including the following:

  1. Draw up a draft paediatric investigation plan (PIP) and submit it to the European Medicines Agency (EMA), through the Paediatric Committee (PDCO), for agreement. The PIP should specify the timing and measures proposed to assess the quality, safety and efficacy of the medicine in the paediatric population. In addition, it should describe any measures to adapt the formulation of the medicinal product to make its use more acceptable, easier, safer or more effective. The proposed PIP is assessed by the PDCO, which may request modifications to the plan. The PDCO then adopts an opinion as to whether or not the proposed studies will generate the necessary data, and if they are justified by the envisaged benefits. The EMA issues a decision, annexing the PDCO's opinion.
  2. Apply for a marketing authorisation including the decision agreeing to the PIP, the results of all studies performed and details of all information collected in compliance with the agreed PIP. The competent authority (i.e. the body that grants marketing authorisations) which has received the application verifies that the PIP has been complied with.
  3. Apply to the national patent offices for a paediatric extension to its SPCs, if the applicant has been issued a marketing authorisation indicating compliance with the PIP.

The paediatric extension for atorvastatin

Pfizer had proposed new pharmaceutical forms for oral atorvastatin, which were more appropriate for children aged 6 years and above than the previously authorised film-coated tablet.

The agreed PIP required three clinical studies. The first was a bioequivalence study to check the bioavailability and effectiveness of the new form in comparison to the existing formulation in healthy adult volunteers. The second was a pharmacokinetic study to determine dosing. The third was a 3-year study of safety and efficacy.

The PIP specified that the first study was to be completed by 30th September 2009 and the second study by 30th December 2009. The third study, however, was only required in the PIP to be commenced by 31st March 2009. In due course an extension to the SPC was granted, on the basis of a decision that the studies conducted by Pfizer were in accordance with the PIP, as the first and second studies had been completed and the third study had been started.

The Court's judgment

Three grounds for revocation were advanced by Dr Reddy's, but all were dismissed by the Court.

First, Dr Reddy's argued that the EMA had acted incorrectly by approving a PIP that required Pfizer merely to commence the third study, and as such the PIP was not lawfully approved and Pfizer was not entitled to the extension. However, the Court instead assessed that the relevant question was whether or not the requirements of the PIP had been fulfilled. It judged that Pfizer had indeed complied by completing the first and second studies, and initiating the third study.

Second, Dr Reddy's argued that, pursuant to Article 45(3) of the regulation, a paediatric extension should be granted only when 'significant studies' contained in the PIP have been completed. It alleged that at no stage had any assessment been performed as to whether either of the two completed studies was significant; it further alleged that they were not significant. The Court decided, however, that Article 45(3) was a transitional provision which related to research performed before the regulation came into effect. Accordingly, it did not apply in this case.

Finally, Dr Reddy's argued that even if it was legitimate for the EMA to approve a PIP that required the initiation but not completion of the third study, Pfizer was not entitled to an extension unless it included the results of the completed third study within its marketing authorisation application. Here, the Court considered that this argument also failed once it had been decided that Pfizer had complied with the PIP.

A further issue in this case related to the interpretation of Article 16 of the SPC regulation (Regulation 469/2009), which sets out that the paediatric extension may be revoked if granted contrary to the requirements of Article 36 of the paediatric regulation. Dr Reddy's argued that this would oblige the Court to revoke the extension of the SPC if it had been granted when this article of the paediatric regulation had not been complied with, but Pfizer argued that it merely gave the Court discretion to do so. On this point, the Court also agreed with Pfizer.

Comment

This decision is of interest in clarifying the interpretation that the UK courts will take with regard to whether or not a PIP has been completed. As SPCs are dealt with on a national basis, however, there is significant potential for contradictory judgments to be issued in different countries, meaning that it is only when questions of this type have been referred to the Court of Justice for the European Union that the issues raised in this case will be definitively addressed. Indeed, bearing in mind that this legislation is relatively new, it is likely that many further issues of interpretation will be raised in due course. This is even more likely because the paediatric extension extends the SPC and so coverage for the authorised medicine, irrespective of the indication, at the tail-end and hence most valuable part of an SPC's life.

Need advice?

Carpmaels & Ransford LLP is a leading firm of European patent and trade mark attorneys based in London. For more information about our firm and our practice, please visit our website at www.carpmaels.com.

This Briefing Note was first published in the IAM IP Newsletter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.